Dr. Bruce Hughes, MD

Neurology Des Moines, IA Male
NPI: 1285748004
Total Payments
$2.3M
2024 Payments
$245,952
Companies
40
Transactions
2,001
Medicare Patients
2,324
Medicare Billing
$182,719

Payment Breakdown by Category

Other$1.7M (74.0%)
Consulting$336,533 (14.5%)
Travel$214,550 (9.3%)
Food & Beverage$46,687 (2.0%)
Education$5,323 (0.2%)

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1.7M 550 73.9%
Consulting Fee $336,533 87 14.5%
Travel and Lodging $214,550 440 9.3%
Food and Beverage $46,687 913 2.0%
Education $5,323 10 0.2%
Honoraria $3,300 1 0.1%

Top Paying Companies

Company Total Records Latest Year
Biogen, Inc. $695,742 567 $0 (2024)
EMD Serono, Inc. $317,615 255 $0 (2024)
Genentech USA, Inc. $295,033 174 $0 (2024)
Novartis Pharmaceuticals Corporation $216,716 212 $0 (2022)
GENZYME CORPORATION $189,886 182 $0 (2024)
E.R. Squibb & Sons, L.L.C. $187,684 123 $0 (2024)
Celgene Corporation $134,605 140 $0 (2024)
Janssen Pharmaceuticals, Inc $98,595 75 $0 (2023)
TG Therapeutics, Inc. $74,152 82 $0 (2024)
Alexion Pharmaceuticals, Inc. $31,105 46 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $245,952 244 EMD Serono, Inc. ($73,802)
2023 $265,775 192 EMD Serono, Inc. ($74,933)
2022 $322,956 236 Biogen, Inc. ($96,942)
2021 $199,683 140 Biogen, Inc. ($59,127)
2020 $177,127 147 Biogen, Inc. ($85,939)
2019 $440,934 408 Biogen, Inc. ($146,584)
2018 $328,395 303 Biogen, Inc. ($122,166)
2017 $338,440 331 Biogen, Inc. ($119,516)

All Payment Transactions

2,001 individual payment records from CMS Open Payments — Page 1 of 81

Date Company Product Nature Form Amount Type
12/30/2024 Celgene Corporation — Food and Beverage Cash or cash equivalent $168.88 General
12/30/2024 E.R. Squibb & Sons, L.L.C. ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $144.88 General
Category: Neuroscience
12/30/2024 E.R. Squibb & Sons, L.L.C. ZEPOSIA (Drug) Travel and Lodging Cash or cash equivalent $24.00 General
Category: Neuroscience
12/23/2024 TG Therapeutics, Inc. BRIUMVI (Drug) Food and Beverage In-kind items and services $3.78 General
Category: Immunology
12/23/2024 TG Therapeutics, Inc. BRIUMVI (Drug) Food and Beverage In-kind items and services $3.73 General
Category: Immunology
12/20/2024 Celgene Corporation ZEPOSIA (Drug) Consulting Fee Cash or cash equivalent $2,400.00 General
Category: Neuroscience
12/20/2024 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $4.38 General
Category: Neuroscience
12/19/2024 TG Therapeutics, Inc. BRIUMVI (Drug) Food and Beverage In-kind items and services $136.70 General
Category: Immunology
12/17/2024 Genentech USA, Inc. Ocrevus (Biological), Ocrevus Zunovo Food and Beverage In-kind items and services $53.12 General
Category: Immunology
12/13/2024 TG Therapeutics, Inc. BRIUMVI (Drug) Food and Beverage In-kind items and services $16.59 General
Category: Immunology
12/13/2024 TG Therapeutics, Inc. BRIUMVI (Drug) Food and Beverage In-kind items and services $10.26 General
Category: Immunology
12/10/2024 Biogen, Inc. TYSABRI (Biological), VUMERITY Food and Beverage In-kind items and services $25.19 General
Category: Neurology
12/09/2024 E.R. Squibb & Sons, L.L.C. ZEPOSIA (Drug) Travel and Lodging Cash or cash equivalent $1,261.20 General
Category: Neuroscience
12/09/2024 E.R. Squibb & Sons, L.L.C. ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $12.01 General
Category: Neuroscience
12/06/2024 Celgene Corporation ZEPOSIA (Drug) Travel and Lodging Cash or cash equivalent $695.09 General
Category: Neuroscience
12/06/2024 Celgene Corporation ZEPOSIA (Drug) Travel and Lodging Cash or cash equivalent $212.19 General
Category: Neuroscience
12/06/2024 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $50.12 General
Category: Neuroscience
12/06/2024 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $31.39 General
Category: Neuroscience
12/06/2024 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $26.54 General
Category: Neuroscience
12/06/2024 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $26.54 General
Category: Neuroscience
12/03/2024 GENZYME CORPORATION — Food and Beverage In-kind items and services $89.17 General
12/02/2024 E.R. Squibb & Sons, L.L.C. ZEPOSIA (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $3,665.00 General
Category: Neuroscience
12/02/2024 E.R. Squibb & Sons, L.L.C. ZEPOSIA (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,815.00 General
Category: Neuroscience
11/20/2024 Amgen Inc. — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $3,850.00 General
11/20/2024 Amgen Inc. — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,650.00 General
123…81»

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 11 476 553 $102,002 $37,923
2022 11 463 530 $95,515 $37,179
2021 13 679 805 $142,560 $56,652
2020 15 706 833 $144,575 $50,966
Total Patients
2,324
Total Services
2,721
Medicare Billing
$182,719
Procedure Codes
56

All Medicare Procedures & Services

56 procedure records from CMS Medicare Utilization — Page 1 of 3

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 144 175 $26,250 $10,862 41.4%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2023 86 95 $20,140 $8,898 44.2%
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes Facility 2023 34 34 $13,158 $4,375 33.3%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2023 20 20 $6,420 $2,401 37.4%
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes Facility 2023 24 37 $5,106 $2,179 42.7%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2023 49 51 $4,998 $1,945 38.9%
95886 Needle measurement of electrical activity in arm or leg muscles, complete study Facility 2023 35 55 $5,720 $1,729 30.2%
99204 New patient office or other outpatient visit, 45-59 minutes Facility 2023 14 14 $3,458 $1,282 37.1%
95910 Nerve conduction, 7-8 studies Facility 2023 18 18 $4,356 $1,248 28.7%
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes Facility 2023 12 12 $3,132 $1,159 37.0%
95909 Nerve conduction, 5-6 studies Facility 2023 14 14 $2,548 $673.18 26.4%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2023 13 14 $3,822 $587.97 15.4%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 13 14 $2,894 $584.72 20.2%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 148 181 $27,150 $11,740 43.2%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 76 79 $16,748 $8,060 48.1%
99223 Initial hospital inpatient care per day, typically 70 minutes Facility 2022 34 34 $13,158 $4,582 34.8%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2022 55 58 $5,684 $2,381 41.9%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2022 16 16 $5,136 $1,834 35.7%
99232 Follow-up hospital inpatient care per day, typically 25 minutes Facility 2022 27 33 $4,554 $1,607 35.3%
95910 Nerve conduction, 7-8 studies Facility 2022 19 20 $4,840 $1,539 31.8%
95886 Needle measurement of electrical activity in arm or leg muscles, complete study Facility 2022 26 44 $4,576 $1,450 31.7%
99204 New patient office or other outpatient visit, 45-59 minutes Facility 2022 15 15 $3,705 $1,422 38.4%
99222 Initial hospital inpatient care per day, typically 50 minutes Facility 2022 14 14 $3,654 $1,316 36.0%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 20 23 $4,646 $689.11 14.8%
95819 Measurement of brain wave activity (eeg), awake and asleep Facility 2022 13 13 $1,664 $558.09 33.5%
123»

About Dr. Bruce Hughes, MD

Dr. Bruce Hughes, MD is a Neurology healthcare provider based in Des Moines, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285748004.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Hughes, MD has received a total of $2.3M in payments from pharmaceutical and medical device companies, with $245,952 received in 2024. These payments were reported across 2,001 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.7M).

As a Medicare-enrolled provider, Hughes has provided services to 2,324 Medicare beneficiaries, totaling 2,721 services with total Medicare billing of $182,719. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.

Practice Information

  • Specialty Neurology
  • Location Des Moines, IA
  • Active Since 08/18/2006
  • Last Updated 03/17/2010
  • Taxonomy Code 2084N0400X
  • Entity Type Individual
  • NPI Number 1285748004

Products in Payments

  • ZEPOSIA (Drug) $267,346
  • OCREVUS (Biological) $207,602
  • TECFIDERA (Drug) $175,219
  • VUMERITY (Drug) $162,377
  • GILENYA (Drug) $124,266
  • Mavenclad (Drug) $116,482
  • TYSABRI (Biological) $115,649
  • AUBAGIO (Drug) $84,706
  • Ponvory (Drug) $71,991
  • LEMTRADA (Drug) $70,926
  • BRIUMVI (Drug) $68,931
  • MAVENCLAD (Drug) $59,065
  • Mavenclad (Biological) $58,613
  • Non-Covered Product (Drug) $49,821
  • Ozanimod (Drug) $40,417
  • Ocrevus (Biological) $40,128
  • MAYZENT (Drug) $26,818
  • PLEGRIDY (Biological) $26,688
  • Rebif (Biological) $24,240
  • AMPYRA (Drug) $22,272

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Neurology Doctors in Des Moines

Michael Jacoby, Md, MD

Neurology — Payments: $247,801

Neurology $247,801

Lynn Rankin, Md, MD

Neurology — Payments: $222,800

Neurology $222,800

Paul Babikian, Md, MD

Neurology — Payments: $162,701

Neurology $162,701

Wendy Zadeh, Md, MD

Neurology — Payments: $138,438

Neurology $138,438

Mark Puricelli, Do, DO

Neurology — Payments: $70,851

Neurology $70,851

Keith Kohout, Do, DO

Neurology — Payments: $53,823

Neurology $53,823